Risk Intelligence
Not Available
Insufficient Data
How strong and defensively sound is the company?
This reading is not available for this company yet.
CTKB · NASDAQ
Sector unavailable · Industry unavailable
$4.61
+1.77%
Close on Sep 11, 2026
Updated 12/18/2023
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
Sector unavailable · Data confidence limited
No Pro Investor Score today
Risk Intelligence is unavailable
Not Available
Insufficient Data
How strong and defensively sound is the company?
This reading is not available for this company yet.
Not Available
Insufficient Data
Does the business have the characteristics needed to create value over many years?
This reading is not available for this company yet.
Not Available
Insufficient Data
Is the underlying business getting stronger or weaker?
This reading is not available for this company yet.
Not Available
Positive disclosed activity
What are important owners actually doing?
This reading is not available for this company yet.
73 / 100
Very Attractive
Is today's price reasonable?
Above average on this measure — and valuation is researched separately from the Suggested Investment Score.
16 / 100
Limited Capital Returns
How effectively does the company reward shareholders?
Weaker than most covered companies on this measure — and capital returns are researched separately from the Suggested Investment Score.
No weakening evidence is recorded in today's readings.
Long-Term Potential is not available for this company, so no long-term reading is shown.
No disclosed ownership reading is available at the required confidence, so ownership is left blank rather than estimated.
CYTEK BIOSCIENCES INC reads 73 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
CYTEK BIOSCIENCES INC reads 16 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting a share count rising about 32.4% a year. Direct capital returns are limited because the company continues reinvesting most of its cash. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare CTKB with other companiesAppears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
60-Second Brief
Too few stored readings exist for this company to summarise honestly.
Composite discovery model
Pro Investor Score™
Risk Intelligence is unavailable. A composite score is only published when every required input is available for this company. Nothing is estimated to fill a gap, and exclusion from the ranking is not a sell instruction.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Ranking updated September 12, 2026
Researched separately
Valuation Intelligence 73 · Very Attractive
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 16 · Limited Capital Returns
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
This company does not currently hold a stored Pro Investor Score, so no contribution breakdown can be shown.
Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.
Loading professional-investor activity…
Stored snapshots only
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Very Attractive
72
Very Attractive
Is this company expensive or inexpensive compared with its own history?
52
Reasonable
How expensive is this stock compared with similar companies?
—
Not Available
How much financial output does an investor receive relative to the price paid?
No positive earnings or cash-flow yield is available, so this lens is not scored.
100
Very Attractive
Does the company's growth help justify the valuation investors are paying?
CYTEK BIOSCIENCES INC reads 73 out of 100 on Valuation Intelligence, recorded as Very Attractive. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current EV/Sales 2.6x · own median 3.5x · peer median 2.8x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Limited Capital Returns
—
Not Applicable — No Dividend
Dividend reliability
This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.
30
Limited Capital Returns
Do buybacks actually reduce shares?
The company spends on share repurchases, but much of that activity offsets share issuance rather than materially reducing the share count.
5
Limited Capital Returns
Is your ownership share protected?
—
Not Available
Can the cash flow support it?
No usable cash-flow or earnings measure is stored, so coverage cannot be confirmed.
5
Limited Capital Returns
Cash returned versus company value
CYTEK BIOSCIENCES INC reads 16 out of 100 on Capital Returns Intelligence (Limited Capital Returns), reflecting a share count rising about 32.4% a year. Direct capital returns are limited because the company continues reinvesting most of its cash.
This company currently retains rather than distributes cash through dividends. Capital Returns Intelligence therefore places more emphasis on its other measurable shareholder-return behaviors according to the frozen V1 methodology.
This company spent cash repurchasing stock, but the share count did not fall meaningfully because it also issued shares. Repurchase spending alone did not increase existing shareholders' ownership.
How returned cash was used
Dividends $0.00 · net repurchases $24.40M · total returned $24.40M
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.
Stored daily snapshots only
| Today | Not ranked | No stored score |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | Not ranked | |
In the company’s own words
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells ("Full Spectrum Profiling" or "FSP" technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.
Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions. It is essential to correlate information derived from multiple cell analysis approaches and to translate what is known at the gene level to the actual cell function. As a result, there is growing demand for deep content through high dimensional cell analysis and for solutions that can provide a complete picture of cellular biological processes and interactions. To achieve this, scientists need to phenotype and isolate rare events or unique populations down to the single-cell level through highly resolvable multi-dimensional cell analysis. While flow cytometry is a widely used tool for single cell analysis, conventional flow cytometry, mass cytometry and early approaches to spectral flow cytometry technologies have historically been challenged due to limited dimensionality, sub-optimal resolution, low throughput, high cost for performance and/or significant technical expertise required to operate systems.
Our patented FSP technology optimizes sensitivity and accuracy through its unique optical and electronic designs that utilize an innovative method of light detection and distribution to a specifically selected number and type of detectors. This patented optics design enables researchers to effectively collect the full range of light emissions in an extremely compact space, resulting in higher resolution and enabling the development of highly complex assays with 50 different colors (individual fluorochromes), supporting 50 biomarkers within just a single tube.
Our FSP cell analyzers, the Cytek Aurora , Northern Lights , and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies by providing a higher level of multiplexing with exquisite sensitivity, more flexibility and increased efficiency, all at a lower cost for performance. Additionally, our Cytek Aurora cell sorter ("Aurora CS system") leverages our FSP technology to further broaden our potential applications across cell analysis by enabling the same number of parameters with the same sensitivity as the Cytek Aurora and Cytek Aurora Evo cell analyzer systems. Each system is supported by our highly intuitive, proprietary embedded SpectroFlo software, our reagents, and our service offerings to provide a comprehensive, end-to-end platform of solutions for our customers.
Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing
Four distinct intelligence areas
31
Exit Review
No prior period to compare
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
—
Insufficient Data
No prior period to compare
Durable business economics and reinvestment characteristics. Independent external validation is pending.
—
Insufficient Data
No prior period to compare
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
—
Insufficient Data
No prior period to compare
No tracked manager filings mapped to this company.
Not enough stored history to chart CTKB yet. A company needs at least two published research or ownership periods before a trend can be shown.
Share price
Closing prices adjusted for splits and dividends, through Sep 11, 2026. Past prices do not indicate future results.
Last stored close $4.61 · +16.4% over the selected range · 64 sessions shown
Balanced evidence
Risk and uncertainty
Public filings · descriptive only
Reporting holders
8
New holders
7
Increasing
1
Reducing
0
Exiting
0
Coverage
Excellent
Positive disclosed activity · Report period 2023-09-30 · Public 12/18/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
No qualifying changes are recorded for this company in the stored research and filing history.
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.